GLP-1 and CGM Convergence Market Forecast to Reach USD 4.47 Billion by 2034

The glp-1 and cgm convergence market is drawing attention from business customers and technology suppliers as its applications and delivery models evolve. Polaris Market Research values the glp-1 and cgm convergence market at USD 1.65 billion in 2025, estimates USD 1.84 Billion for 2026, and projects USD 4.47 Billion by 2034. Its published compound annual growth rate is 11.7% for 2026–2034. The figures are presented in the latest market outlook published by Polaris Market Research, which also identifies changes in customer demand and industry infrastructure as factors behind the forecast. Rather than treating the projection in isolation, the page connects market value with the products, services and end users counted in its scope.

Market Growth and Industry Outlook

Increasing GLP-1 adoption, drug price changes, evidence from the CONNECT trial and interest in CGM access for people with non-insulin-treated type 2 diabetes shape the market. The 2025 base and 2026 estimate provide the reference points for the projection through 2034. The forecast should be read as Polaris Market Research's published market estimate rather than a guarantee of individual company sales or project outcomes.

The convergence connects real-time glucose tracking with medication use in diabetes management, obesity treatment and metabolic-health monitoring. These applications show why the market is relevant to multiple types of commercial organization.

Key Market Drivers and Emerging Trends

One prominent theme is continuous glucose monitoring, which appears alongside other market-specific technologies and delivery approaches. The defined market counts continuous glucose monitoring sensors and related app revenue from people taking GLP-1 receptor agonists; it excludes drug sales. The way these elements interact helps explain the market's operating structure without requiring claims about unreported adoption rates. The report also links market activity to GLP-1 receptor agonists, giving customers a concrete technology-related topic to evaluate.

For organizations following the sector, continuous glucose monitoring and GLP-1 receptor agonists are relevant because they belong to the products, functions or use cases discussed by Polaris. The distinction keeps a market outlook grounded in what the published page actually reports.

Segment and Application Insights

The published segmentation adds detail to the overall forecast. Injectable GLP-1 and dual agonists represented 71.35% in 2025; type 2 diabetes patients using GLP-1 accounted for 63.54% of the relevant CGM user market. These figures describe particular categories and their stated periods, not the market as a whole. Keeping the denominator and reference year attached to each figure prevents an application share from being confused with a component share or a regional measure.

The source also discusses type 2 diabetes management as part of the relevant product or application context. The convergence connects real-time glucose tracking with medication use in diabetes management, obesity treatment and metabolic-health monitoring. A reader comparing vendors should distinguish the solution being delivered from the task it supports; both can appear in a report but need not represent identical market segments.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:

https://www.polarismarketresearch.com/industry-analysis/glp-1-and-cgm-convergence-market

Regional Market Perspective

North America is identified as the leading market, with 68.42% in 2025. The page identifies Asia Pacific, with a 15.42% CAGR as an important regional growth reference. Leadership in a stated year and the fastest expected rate of increase are different measures; the source presents them separately. Regional variations therefore should not be translated into invented country sales or treated as evidence that all markets move at the same pace. The source context also includes type 2 diabetes management.

The stated regional distinctions matter for companies assessing geographic exposure and customer needs. They also underline why a reported leading region cannot automatically be called the fastest-growing region. Polaris provides its regional figures as part of a broader forecast that includes the market's applications and technology structure.

Competitive Landscape

Among the named participants are Abbott Laboratories, DexCom, Eli Lilly, Novo Nordisk, Senseonics and Signos. The source context also includes metabolic health monitoring.

Competition can be considered in relation to metabolic health monitoring and the solutions described in the source. Businesses reviewing the sector should keep the page's actual scope separate from any broader activity of the companies mentioned.

Future Market Outlook

The outlook through 2034 brings together real-time glucose data, stated demand factors and the range of uses described by Polaris Market Research. The reported projection of USD 4.47 Billion and 11.7% CAGR reflects the source's defined forecast period. It should not be converted into a prediction about a particular company, contract or individual application. The source context also includes real-time glucose data.

For B2B readers, the practical value of the glp-1 and cgm convergence market outlook is its combination of a clearly stated market boundary, an explicit forecast, segmentation and regional comparisons. Those elements offer a consistent way to discuss industry momentum while maintaining a distinction between reported market facts and decisions that individual organizations must make for themselves.

More Trending Latest Reports By Polaris Market Research:

EV Battery Market

Pre-engineered Building Market

Used Cooking Oil (Uco) Market

Aircraft Leasing Market

Vibration Monitoring Market

4D Printing Market

Aerospace Coatings Market